Eduardo Díaz‐Rubio

Author

Eduardo Díaz‐Rubio

Also Known As

Académico de Número de la Real Academia Nacional de Medicina de España – Oncología, D. Er, Diaz-Rubio, E., Díaz-Rubio, Eduardo, E DIAZRUBIO, E Diaz Rubio, E Diaz-Rubio, E Diaz-Rubio García, E DiazRubio, E Díaz-Rubio

602

Publications

22.8K

Citations

H-Index

124

Concepts

All Affiliations

Hospital Clínico San Carlos Hospital Universitario Reina Sofía Instituto de Investigación Sanitaria del Hospital Clínico San Carlos Marqués de Valdecilla University Hospital Universidad Complutense de Madrid

About

Eduardo Díaz‐Rubio is an author at Hospital Clínico San Carlos specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	40	118	9.7K
2	Health Sciences	16	24	887
3	Public Health	7	7	168
4	Natural Sciences	1	1	20
5	Biochemistry	1	1	20

Eduardo Díaz‐Rubio

199

Publications

19.9K

Citations

H-Index

Page 1

	Year	Citations
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer Eric Van Cutsem, Andrés Cervantes, René Adam, Annals of Oncology Surgical OncologyEsmo Consensus GuidelinesGastrointestinal OncologyMedicineCancer Management	2016	3.3K
Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study Leonard B. Saltz, Stephen Clarke, Eduardo Díaz‐Rubio, Journal of Clinical Oncology	2008	3K
Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy Jan B. Vermorken, José Trigo, Ricardo Hitt, Journal of Clinical Oncology	2007	996
Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer Jim Cassidy, Stephen Clarke, Eduardo Díaz‐Rubio, Journal of Clinical Oncology	2008	858
Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data François‐Clément Bidard, Dieter Peeters, Tanja Fehm, The Lancet Oncology Metastatic Breast CancerBreast OncologyClinical ValidityIndividual Patient DataMedicine	2014	815
Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database Jan Franko, Qian Shi, Jeffrey P. Meyers, The Lancet Oncology Gastrointestinal OncologyIndividual Patient DataMedicineGastroenterologyColorectal Cancer	2016	628
XELOX (Capecitabine Plus Oxaliplatin): Active First-Line Therapy for Patients With Metastatic Colorectal Cancer Jim Cassidy, Josep Tabernero, Chris Twelves, Journal of Clinical Oncology	2004	522
Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines D. Machover, Eduardo Díaz‐Rubio, Aimery de Gramont, Annals of Oncology OncologyMedicineColorectal CancerAdvanced Colorectal CarcinomaCancer Treatment	1996	433
Phase II Trial of Cetuximab in Combination With Fluorouracil, Leucovorin, and Oxaliplatin in the First-Line Treatment of Metastatic Colorectal Cancer Josep Tabernero, Eric Van Cutsem, Eduardo Díaz‐Rubio, Journal of Clinical Oncology	2007	337
Phase III Study of Capecitabine Plus Oxaliplatin Compared With Continuous-Infusion Fluorouracil Plus Oxaliplatin As First-Line Therapy in Metastatic Colorectal Cancer: Final Report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial Eduardo Díaz‐Rubio, Josep Tabernero, Auxiliadora Gómez‐España, Journal of Clinical Oncology	2007	267

Page 1